Growth Funding Salvo Health just secured an 8.5M Series A funding round in January 2026 led by multiple investors, signaling strong investor confidence and potential capital for expanding client acquisitions, platform enhancements, and market reach within GI and metabolic liver care.

Enterprise Collaboration The platform targets providers including GI private practices, primary care population health ACOs, and health systems, offering interdisciplinary follow-on care teams. This creates cross-sell opportunities with hospital networks and managed care organizations seeking wraparound care models and new revenue streams.

RPM-Based Revenue Salvo Health leverages remote patient monitoring covered by insurance to enable continuous care and value-based care transitions. This aligns with health systems pursuing bundled services and performance-based payments, suggesting upsell to institutions adopting RPM-enabled care models.

Clinical Advisory With Dr. Robert Hirten joining the Clinical Advisory Board in 2025, Salvo Health strengthens clinical credibility and case-building for payer discussions, facilitating partnerships with medical groups and health plans seeking validated chronic care platforms.

Strategic Partners Recent high-profile Series A investors and venture backing (ManchesterStory, City Light Capital, Threshold Ventures, Artemis Fund, Contour Venture Partners) indicate a strong network for co-selling, pilot programs, and introductions to potential health system and private practice clients.